No disease-modifying agents have been developed to treat myelodysplastic syndromes (MDS). All pharmacological approaches to treat the disease—growth factor stimulants (e.g., erythropoietin-stimulating agents), lenalidomide, luspatercept, and hypomethylating agents—are designed to ameliorate the symptoms and extend patients’ survival. The MDS pipeline is diverse in its approaches to address both lower- and higher-risk MDS; it includes injectable biologics, small-molecule inhibitors with novel MOAs, and reformulations / modifications of current therapies. In this report, we assess the clinical and commercial opportunities in the MDS space through a comprehensive analysis of surveyed hematologists’ treatment drivers and goals and their perceptions of the performance of key current therapies against these goals.
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 60 U.S. and 30 European hematologists-oncologists fielded in March 2022
Key companies: Acceleron, Bristol-Myers Squibb (BMS), Novartis, Otsuka, Sanofi, Taiho Oncology
Key drugs: Antithymocyte globulin, azacitidine, decitabine / cedazuridine, deferasirox, growth factor stimulants, lenalidomide, luspatercept